Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?
- PMID: 27036971
- PMCID: PMC5452418
- DOI: 10.1158/2326-6066.CIR-16-0011
Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?
Abstract
Solid tumors are complex organ-like structures. The potential of normal neighboring cells to contribute to the initiation, progression, and metastasis of epithelial-derived carcinomas has long been appreciated. However, the role of host cells has proven complex. Through multiple local and systemic mechanisms, nontransformed host cells can promote transition from a tumor-resistant to tumor-permissive environment, drive neoplastic transformation of epithelial cells, promote tumor growth, progression, and metastasis, but also constrain tumorigenesis. This complexity reflects the spatially and temporally dynamic involvement of multiple cell types and processes, including the development and recruitment of inflammatory, immune, endothelial, and mesenchymal stromal cells, and the remodeling of extracellular matrix. Our mechanistic understanding, as well as our ability to translate advances in our understanding of these mechanisms for therapeutic benefit, is rapidly advancing. Further insights will depend on delineating pathways that mediate the communication networks between inflammatory and immune cells with tumor and mesenchymal stromal cells and extracellular matrix. Here, we discuss the diversity of mesenchymal stromal cell populations and how context can dictate either their promotion or constraint of tumorigenesis. We review evidence for plasticity that allows for reprogramming of stromal cells and how tumor immunogenicity and desmoplasia influence the balance of immune-independent and immune-dependent regulation of tumor growth. The pivotal roles of matrix and mesenchymal stromal cells in modulating inflammation, antitumor immunity, and the efficacy of immune-based therapies are discussed. These concepts have emerged from data obtained from tumors of multiple organs, but we focus mostly on studies of pancreatic ductal adenocarcinomas.
©2016 American Association for Cancer Research.
Conflict of interest statement
The laboratory of E. Puré received research support from Novartis and shares inventor status on a pending patent.
Figures
Similar articles
-
Radiation-Induced Transformation of Immunoregulatory Networks in the Tumor Stroma.Front Immunol. 2018 Jul 26;9:1679. doi: 10.3389/fimmu.2018.01679. eCollection 2018. Front Immunol. 2018. PMID: 30105016 Free PMC article. Review.
-
Tumor-host interactions: the role of inflammation.Histochem Cell Biol. 2008 Dec;130(6):1079-90. doi: 10.1007/s00418-008-0527-3. Epub 2008 Oct 25. Histochem Cell Biol. 2008. PMID: 18953558 Review.
-
[Role of the stroma in the initiation and progression of tumors].Orv Hetil. 2015 Nov 8;156(45):1816-23. doi: 10.1556/650.2015.30294. Orv Hetil. 2015. PMID: 26522855 Review. Hungarian.
-
Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer.Immunotherapy. 2011 Oct;3(10):1253-64. doi: 10.2217/imt.11.124. Immunotherapy. 2011. PMID: 21995575 Review.
-
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.J Immunother Cancer. 2018 Jul 3;6(1):65. doi: 10.1186/s40425-018-0376-0. J Immunother Cancer. 2018. PMID: 29970158 Free PMC article. Review.
Cited by
-
Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.Genome Med. 2020 Sep 29;12(1):80. doi: 10.1186/s13073-020-00776-9. Genome Med. 2020. PMID: 32988401 Free PMC article.
-
[18F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[18F]FDG PET/CT.Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):1205-1215. doi: 10.1007/s00259-022-06067-2. Epub 2022 Dec 10. Eur J Nucl Med Mol Imaging. 2023. PMID: 36495325 Free PMC article.
-
Targeting of activated fibroblasts for imaging and therapy.EJNMMI Radiopharm Chem. 2019 Jul 25;4(1):16. doi: 10.1186/s41181-019-0069-0. EJNMMI Radiopharm Chem. 2019. PMID: 31659499 Free PMC article. Review.
-
Establishment of a tumor immune microenvironment-based molecular classification system of breast cancer for immunotherapy.Aging (Albany NY). 2021 Nov 11;13(21):24313-24338. doi: 10.18632/aging.203682. Epub 2021 Nov 11. Aging (Albany NY). 2021. PMID: 34762599 Free PMC article.
-
Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects.J Immunother Cancer. 2021 Oct;9(10):e002505. doi: 10.1136/jitc-2021-002505. J Immunother Cancer. 2021. PMID: 34607895 Free PMC article.
References
-
- Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309–22. - PubMed
-
- Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392–401. - PubMed
-
- Jacob M, Chang L, Pure E. Fibroblast activation protein in remodeling tissues. Curr Mol Med. 2012;12:1220–43. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources